Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Ionis Pharmaceuticals Inc shares valued at $48,416 were sold by Monia Brett P on Jul 11 ’25. At $41.74 per share, Monia Brett P sold 1,160 shares. The insider’s holdings dropped to 179,820 shares worth approximately $7.58 million following the completion of this transaction.
Also, Hayden Michael R purchased 15,000 shares, netting a total of over 477,900 in proceeds. Following the buying of shares at $31.86 each, the insider now holds 50,219 shares.
Before that, Birchler Brian had sold 680 shares from its account. In a trade valued at $19,292, the EVP, Corp and Development Ops traded Ionis Pharmaceuticals Inc shares for $28.37 each. Upon closing the transaction, the insider’s holdings decreased to 680 shares, worth approximately $2.39 million.
As published in a research note from Barclays on July 01, 2025, Ionis Pharmaceuticals Inc [IONS] has been rated up from an Equal weight to an Overweight and the price target has been revised to $57. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in early April. As of March 31, 2025, Redburn Atlantic has initiated its “Neutral” rating for IONS. Earlier on August 02, 2024, BMO Capital Markets downgraded its rating. Their new recommendation was “a Market perform” for IONS stock which previously was a “an Outperform”.
Analyzing IONS Stock Performance
On last trading session,, Ionis Pharmaceuticals Inc [NASDAQ: IONS] plunged -1.40% to $42.17. The stock’s lowest price that day was $42.125, but it reached a high of $43.295 in the same session. During the last five days, there has been a drop of approximately -0.50%. Over the course of the year, Ionis Pharmaceuticals Inc shares have dropped approximately -11.35%.
Support And Resistance Levels for Ionis Pharmaceuticals Inc (IONS)
RSI (Relative Strength Index) is 62.08 on the 14-day chart, showing neutral technical sentiment.
Is Ionis Pharmaceuticals Inc subject to short interest?
Stocks of Ionis Pharmaceuticals Inc saw a sharp steep in short interest on 2025-06-13 dropping by -1.04 million shares to 14.23 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 15.27 million shares. A decline of -7.31% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 10.23 of the overall float, the days-to-cover ratio (short ratio) decline to 10.23.
Which companies own the most shares of Ionis Pharmaceuticals Inc (IONS)?
In terms of Ionis Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 55 in the next 12 months, up nearly 28.59% from the previous closing price of $42.77. Analysts anticipate Ionis Pharmaceuticals Inc stock to reach 77 by 2025, with the lowest price target being 28. In spite of this, 14 analysts ranked Ionis Pharmaceuticals Inc stock as Buy at the end of 2025. On July 24, 2024, Leerink Partners assigned a price target of “an Outperform” to the stock and upgraded coverage with a $62.
